High TNF-α and low IL-2 producing T cells characterize active disease in Takayasu's arteritis

Tripathy, Naresh Kumar; Gupta, Prem Chand; Nityanand, Soniya

doi:10.1016/j.clim.2005.09.010

Cited by 57 publications

(33 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interleukin (IL)-6, RANTES (CCL8), and IL-18 serum concentrations have been found to be higher during the active phase of TA patients than in patients in remission and in healthy control subjects, correlating closely with the disease activity [2][3][4]. Although IL-12 along with tumor necrosis factor (TNF)-␣, IFN-␥, and IL-2 levels were not found to be different between the groups in the above-mentioned study, significantly increased levels of IL-12 were observed more recently in patients with active TA, indicating that the proinflammatory and Th1 polarizing IL-12 might be an important mediator of inflammation in TA [5].…”

Section: Introductionmentioning

confidence: 99%

Interleukin (IL)–12, IL-2, and IL-6 Gene Polymorphisms in Takayasu’s Arteritis from Turkey

et al. 2006

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Interleukin (IL)–12, IL-2, and IL-6 Gene Polymorphisms in Takayasu’s Arteritis from Turkey

et al. 2006

View full text Add to dashboard Cite

“…A TA patogenezisében ugyanakkor felmerül a humorális immunválasz szerepe is, a Takayasu-betegek többségében endothelsejt-ellenes antitesteket mutattak ki [17], amelyek az endothelialis gyulladá-sos citokinek, adhéziós molekulák termelődésének serkentésével fokozzák az erek destrukcióját [18]. A vascularis laesiókban leírták az IL-6, IL-12, IL-18, E-szelektin, VCAM-1 (vascular cell adhesion molecule-1 -vascularis sejtadhéziós molekula-1), ICAM-1 (inter cellular cell adhesion molecule-1 -intercelluláris sejtadhéziós molekula-1) szintjének szignifikáns emelkedését [19][20][21][22], valamint remisszióban levő páciensekkel összehasonlítva aktív TA-betegben a tumornekrózis-faktor-alfa (TNF-α) emelkedését és csökkent IL-2-szintet [23].…”

Section: Takayasu-arteritisunclassified

Nagyérvasculitisek korszerű kezelése

Szabó

Kiss

2017

Orvosi Hetilap

View full text Add to dashboard Cite

A nagyérvasculitisek közé sorolt óriássejtes arteritisben és Takayasu-arteritisben közös az érfal patogenetikai eltérése, ez alapján felmerül, hogy nem két külön entitásról, hanem egy betegség két megnyilvánulási formájáról van szó. Kezelésükben továbbra is a glükokortikoidé a vezető szerep, szükség esetén cyclophosphamiddal, azatioprinnal, mycofenolat mofetillel kiegészítve. Tekintettel arra, hogy a betegek jelentős része a konvencionális betegségmódosító szerek mellett is szteroiddependens, egyre több klinikai tapasztalat gyűlik a hosszú távú mellékhatások elkerülése ér-dekében adott biológiai terápiás szerek hatékonyságáról. A szerzők célja az új terápiás lehetőségek áttekintése. A tumornekrózis-faktor-alfa-gátlókkal jó terápiás eredmények vannak Takayasu-arteritisben, de óriássejtes arteritisben nem bizonyultak kellően hatékonynak, ugyanakkor az interleukin-6-gátlóval mindkét betegségben szignifikáns javulást sikerült elérni. Az abatacept és az ustekinumab is ígéretesnek tűnik a nagyérvasculitisek kezelésében. Orv. Hetil., 2017, 158(1), 5-12.Kulcsszavak: óriássejtes arteritis, Takayasu-arteritis, tocilizumab, abatacept, ustekinumab Recent advances in the treatment of large vessel vasculitidesGiant cell arteritis and Takayasu arteritis classified to large vessel vasculitides have similar histopathology in the vascular wall proposing that these entities can be different phenotypes on a spectrum of a single disorder. Glucocorticoids are the mainstay of therapy combined with cyclophosphamide, azatioprine and mycofenolate mofetil, when it is required. However, a significant proportion of patients are glucocorticoid-dependent despite of the conventional disease-modifying antirheumatic drugs and suffer from serious side effects of the steroids, therefore alternate options for more effective disease management are needed. The article reviews the advances in the treatment of large vessel vasculitides. Tumor necrosis factor-alpha inhibitors seem to be effective in Takayasu arteritis, but have a little benefit in giant cell arteritis. Interleukin-6 inhibitor appears very promising in both refractory giant cell arteritis and Takayasu arteritis as well. Abatacept and ustekinumab also seem to be a good choice for the therapy. ÖSSZEFOGLALÓ KÖZLEMÉNYRövidítések BAFF = (B-cell activating factor) B-sejt-aktiváló faktor; CTLA-4 = (cytotoxic T-lymphocyte-associated protein 4) citotoxikus Tlymphocyta-asszociált fehérje-4; CYC = cyclophosphamid; DMARD = (disease-modifying antirheumatic drug) betegség-módosító antireumatikus szer; GC = glükokortikoid; GCA = (giant cell arteritis) óriássejtes arteritis; HLA = humán leukocyta-antigén; ICAM-1 = (intercellular cell adhesion molecule-1) intercelluláris sejtadhéziós molekula-1; IFN-γ = interferon-γ; IL = interleukin; ISU = immunszuppresszív; LVV = (large vessel vasculitis) nagyérvasculitis; MTX = methotrexat; PDGF = (platelet-derived growth factor) thrombocytaeredetű növeke-dési faktor; ROCK = (rho kinase) rho-kináz; TA = Takayasuarteritis; TCZ = tocilizumab; TGF-β = (transforming grow...

show abstract

“…Secondly, TNF-α is upregulated in peripheral blood mononuclear cells [21] and an increased TNF-α serum concentration [22] is seen in patients with TA compared to healthy controls. CD3 + T cells from patients with active disease have higher TNF-α production compared to patients in remission or to healthy controls [23]. Lastly, in preliminary studies, anti-TNF therapy has been successfully employed in patients with TA refractory to other immunosuppressive therapies [24].…”

Section: Schlüsselwörtermentioning

confidence: 99%

Aortenaneurysma bei Patienten mit Takayasu-Arteriitis: Kasuistik

Perrotta

Rådberg

Perrotta

et al. 2011

Herz

View full text Add to dashboard Cite

Takayasu disease is a non-specific inflammatory disease of the arterial system. Although various etiopathogenetic hypotheses have been formulated, its etiology remains unknown. The aorta and its main branches are predominantly involved in the disease, which is a form of panarteritis, starting with inflammation of the adventitia followed by involvement of the media and intima. It has been more frequently described in young oriental female patients. However, a worldwide distribution is being recognized. Arterial stenosis represents the most frequently diagnosed manifestation. Progression of the flogistic process may lead to stenosis of the aorta and supraaortic vessels, compromising arterial circulation to the brain and upper limbs. Aneurysm presentation may also rarely occur. Based on a recently treated case, the authors report on the clinical presentation, concomitant inflammatory diseases, current diagnostic methods, and management of this disease.

show abstract

High TNF-α and low IL-2 producing T cells characterize active disease in Takayasu's arteritis

Cited by 57 publications

References 15 publications

Interleukin (IL)–12, IL-2, and IL-6 Gene Polymorphisms in Takayasu’s Arteritis from Turkey

Interleukin (IL)–12, IL-2, and IL-6 Gene Polymorphisms in Takayasu’s Arteritis from Turkey

Nagyérvasculitisek korszerű kezelése

Aortenaneurysma bei Patienten mit Takayasu-Arteriitis: Kasuistik

Contact Info

Product

Resources

About